Cyclo Therapeutics Inc.
0.67
-0.02 (-2.33%)
At close: Jan 15, 2025, 9:37 AM

Company Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.

Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.

The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease.

In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019.

Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.

Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc. logo
Country United States
IPO Date May 3, 2000
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 8
CEO N. Scott Fine

Contact Details

Address:
6714 NW 16th Street
Gainesville, Florida
United States
Website https://www.cyclotherapeutics.com

Stock Details

Ticker Symbol CYTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000922247
CUSIP Number 550241103
ISIN Number US23254X2018
Employer ID 59-3029743
SIC Code 2860

Key Executives

Name Position
N. Scott Fine Chief Executive Officer & Director
Dr. Jeffrey L. Tate Ph.D. Chief Operating Officer, Chief Quality Officer & Director
Joshua M. Fine Chief Financial Officer & Secretary
C. E Strattan Founder & Director
Dr. Karen Mullen FFPM Interim Chief Medical Officer
Lori McKenna Global Head of Patient Advocacy
Michael Eric Lisjak Senior Vice President of Business Development & Chief Regulatory Officer

Latest SEC Filings

Date Type Title
Jan 13, 2025 4 Filing
Jan 13, 2025 8-K Current Report
Jan 03, 2025 8-K Current Report
Dec 23, 2024 8-K Current Report
Dec 18, 2024 10-K/A [Amend] Annual Report
Dec 05, 2024 8-K Current Report
Nov 26, 2024 10-K/A [Amend] Annual Report
Nov 18, 2024 4 Filing
Nov 18, 2024 4 Filing
Nov 18, 2024 4 Filing